Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma.
Rusthoven
J J
JJ
Hamilton Regional Cancer Center, Ontario, Canada.
Eisenhauer
E
E
Mazurka
J
J
Hirte
H
H
O'Connell
G
G
Muldal
A
A
Lu
H X
HX
Onetto
N
N
Swenerton
K
K
Jeffrey
J
J
D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage
D007377:Interleukin-3; D011994:Recombinant Proteins; D016190:Carboplatin